Sodium Sulfate (Mirabilitum Depuratum) Veterinary Grade API is the purified decahydrate of sodium sulfate, Na₂SO₄·10H₂O, controlled for use in tablets, injections, capsules, powders, granules, premix, and solutions. The hydrated lattice contains 55.9% w/w water of crystallisation and has a formula weight of 322.20 g/mol; this distinguishes the product from anhydrous sodium sulfate (142.04 g/mol) and from magnesium sulfate heptahydrate (246.47 g/mol) in mass balance and formulation handling. The API is supplied as a white or almost white crystalline powder or colourless crystals, freely soluble in water and practically insoluble in ethanol. Manufacturer article codes are supplier-specific, so no unified veterinary model designation exists across compendial frameworks. Batch release is customarily controlled against pharmacopoeial monographs for sodium sulfate decahydrate plus the additional microbial, endotoxin, and elemental impurity requirements applied to veterinary APIs. Formulators should verify target animal species eligibility, withdrawal periods, and national veterinary medicinal product or feed additive registration requirements before use.

Why Does Water of Crystallisation Complicate Tablet and Capsule Manufacture?

In solid oral dosage forms, the decahydrate does not behave as an inert filler because lattice water can migrate during wet granulation, drying, and compression. On a production-scale high-shear mixer, granulation endpoint control based on impeller power alone is not reliable when sodium sulfate decahydrate is present above 10% w/w; released hydration water behaves as an internal granulating solvent and can produce local over-wetting that is not visible in the mass curve. Drying to compendial limits is monitored by USP <731> or Ph. Eur. 2.2.32, but total water by Karl Fischer titration (Ph. Eur. 2.5.12) includes the stoichiometric hydration water and therefore does not indicate the free-moisture content required for tablet hardness control. Batch-to-batch variance in crystal habit and particle size is measured by analytical sieving per USP <786> or laser diffraction per ISO 13320:2020; fines below 75 µm can increase tablet friability and cause dusting on rotary tablet presses fitted with forced feeders.

For capsules, the fill material should be dried to a free-moisture specification that prevents softening of gelatin shells. Powder retained above 60% RH may produce shell deformation during stability storage. Direct compression is generally not recommended for high-dose tablets because the crystalline API has limited plastic deformation; wet granulation or roller compaction is preferred. A high-shear granulation route using hypromellose at 2%–4% w/w is feasible, but sulfate ions may compete for water with the binder, shifting gel formation and reducing granule strength. Because the decahydrate transition temperature is about 32.4°C, processing areas for mills, blenders, and tablet presses should be maintained below this value to avoid surface melting and caking. Published quantitative rheological data for this specific veterinary formulation are limited; small-scale factorial studies should therefore be run before scale-up to production batches above 100 kg.

Terminal Sterilisation and Filtration Limits for Injection Solutions

Solutions for injection are prepared by dissolving the API in Water for Injections. At 20°C, aqueous solubility of sodium sulfate decahydrate is approximately 19.5 g/100 mL; at 32.4°C, solubility rises to about 49.7 g/100 g water. Above the transition temperature, the stable phase is the anhydrous salt, and solubility decreases to about 42.5 g/100 g at 100°C. Cooling a concentrated solution can crystallise the decahydrate and block filling needles. A 1% w/v sodium sulfate decahydrate solution has an approximate osmolarity of 93 mOsm/L, which is markedly hypotonic relative to mammalian plasma and should not be presented as an isotonic diluent without tonicity adjustment. Terminal moist-heat sterilisation at 121°C for 15 min is suitable only after container-closure system qualification under USP <1207>; sulfate anions can promote glass delamination and interaction with elastomeric stopper additives, so an extractables study under Ph. Eur. 3.2.9 is normally required. Filtration through a sterilising-grade membrane is documented by bacterial retention testing per ASTM F838-20. Sodium sulfate solutions are incompatible with calcium-containing injections because calcium sulfate precipitation is possible; admixture should not be performed without documented compatibility data.

For oral powders, granules, and feed premixes, particle-size distribution and bulk density are matched to the carrier system and dosing device. In veterinary powders intended for in-water or in-feed administration, free-flowing character is commonly achieved by blending the crystalline API with fractionated carriers such as lactose monohydrate or ground limestone. Segregation is controlled by keeping the D50 of the active and carrier within a defined ratio. Because sodium sulfate decahydrate can lose surface water under dry storage and may cake at elevated atmospheric moisture, a moisture-barrier package with a low water-vapour transmission rate should be selected. In premix applications, sulfate load contributes to total dietary sulfur. For beef cattle, maximum tolerable dietary sulfur concentration is approximately 0.4% dry matter according to NRC guidance; higher intake is associated with increased risk of polioencephalomalacia. No uniform international premix limit applies to all species, so the formulation should be checked against national veterinary feed rules for the target animal class.

If Anhydrous Sodium Sulfate or Magnesium Sulfate Heptahydrate Is Replaced by the Decahydrate

Replacement calculations must use the hydrated molecular form because sodium sulfate decahydrate contains 14.3% w/w sodium and 29.8% w/w sulfate, whereas anhydrous sodium sulfate contains 32.4% sodium and 67.6% sulfate. Magnesium sulfate heptahydrate contains no sodium but provides about 39.0% sulfate and introduces magnesium. Therefore, in a fixed tablet or premix formula, the mass of active ingredient cannot be changed without correcting for water of crystallisation and for the changed cation-anion ratio. The comparative values relevant at 20°C are summarised below.

In practice, the decahydrate may be preferred over the anhydrous form when slower dissolution, a cooling effect, or storage in a non-anhydrous processing environment is desired. However, the anhydrous form has higher sulfate density per gram and may reduce tablet size. Magnesium sulfate heptahydrate introduces magnesium and a distinctive bitter taste that affects feed palatability. Sodium sulfate decahydrate is also distinct from sodium chloride in that the sulfate ion contributes to intestinal water retention without adding chloride to extracellular fluid; this distinction is relevant in animals requiring an osmotic cathartic without chloride loading. Published veterinary pharmacopoeial or clinical data for this specific API configuration are limited; dose selection should be based on species-specific formularies and not on human laxative monographs.

In liquid solutions intended for oral use, the API is dissolved to a specified concentration and preserved according to the microbial quality requirements of the target species. Solution pH is usually near neutral, but concentration-dependent endothermic dissolution of the decahydrate can lower the temperature of the bulk liquid during compounding. Jacketed mixing vessels with temperature control should be used for concentrations above 10% w/v. Because sulfate is a divalent anion, solubility is altered in the presence of other electrolytes; common-ion effects from sodium chloride or sodium citrate may reduce the maximum solute load. Long-term stability samples should include visible precipitation, pH, assay, and microbial examination at 25°C/60% RH and 40°C/75% RH conditions following ICH Q1A(R2) where applicable.

Release specifications for veterinary-grade sodium sulfate decahydrate are determined by route of administration. For non-sterile oral powders and premixes, microbial enumeration USP <61> and absence of specified microorganisms USP <62> are applied. For injections, bacterial endotoxin testing USP <85> is added; the limit is calculated from dose and route. For example, an injection administered at 1 g/kg with an endotoxin limit of 5 EU/kg would require an API limit of 5 EU/g. Elemental impurities are controlled under ICH Q3D, and residual solvents are controlled under the applicable pharmacopoeial general chapter. Sulfate content can be verified by precipitation as barium sulfate after dissolution; loss on drying and Karl Fischer water are not interchangeable tests. Loss on drying drives off surface water and most lattice water, while Karl Fischer titration measures total water and must be converted to the decahydrate stoichiometry. Because no single global monograph for “Mirabilitum Depuratum” exists, marketing authorisation applicants should align the specification with the relevant national veterinary pharmacopoeia and the manufacturer’s validated release methods.